Modus Therapeutics Investor Relations Material

Modus Therapeutics AB is a healthcare company engaged in the development of drugs for rare diseases. Its product Slevaoxin, is focused on alleviating the elevated levels of neutrophil extracellular traps, which could reduce the widespread damage to organs and tissues, and frequently leads to life-threatening organ failure and death. It also develops MPC-06-ID, a drug candidate to address infantile onset Idiopathic nephrotic syndrome in children below the age of 2.